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Snail1 transcriptional repressor is a major inducer of epithelial-to mesenchymal transition but is very limitedly
expressed in adult animals. We have previously demonstrated that Snail1 is required for the maintenance of
mesenchymal stem cells (MSCs), preventing their premature differentiation. Now, we show that Snail1 controls the
tumorigenic properties of mesenchymal cells. Increased Snail1 expression provides tumorigenic capabilities to
fibroblastic cells; on the contrary, Snail1 depletion decreases tumor growth. Genetic depletion of Snail1 in MSCs that
are deficient in p53 tumor suppressor downregulates MSC markers and prevents the capability of these cells to
originate sarcomas in immunodeficient SCID mice. Notably, an analysis of human sarcomas shows that, contrarily to
epithelial tumors, these neoplasmsdisplay high Snail1 expression. This is particularly clear for undifferentiated tumors,
which are associatedwith poor outcome. Together, our results indicate a role for Snail1 in the generation of sarcomas.
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Snail1 is a transcriptional factor induced at early phases of epithelial-
to-mesenchymal transition (EMT) and required for the initiation of
this process [1–3]. Snail1 ectopic expression promotes significant
changes in gene expression downregulating epithelial markers, such as
E-cadherin, and increasing the synthesis of genes of the mesenchymal
lineage. Snail1 genetic depletion prevents EMT induced by several
extracellular stimuli both in cell lines and during early embryo
development [1]. However, Snail1 expression is not maintained in
most adult mesenchymal cells: Snail1 is not expressed by tissue-
resident fibroblasts and is only detected in these cells when activated,
such as during the process of wound healing or in the stroma of
several types of epithelial tumors [4]. Actually, although the study of
this factor has been limited by the poor quality of the antibodies
recognizing it, most reliable studies show a limited expression of this
transcriptional factor in epithelial neoplasias. In these tumors, Snail1
is restricted to few cells in the tumor-stroma interface in areas of
invasion or in cells next to areas of inflammation [4,5].
We have recently demonstrated that Snail1 is expressed by
mesenchymal stem cells (MSCs) [6]. In these cells, Snail1 is required
for the maintenance of the undifferentiated state; Snail1 depletion
facilitates their differentiation to adipocytes or osteoblasts and
precludes the block on these processes caused by transforming
growth factor β (TGF-β). Accordingly, Snail1 obliteration in adult
animals promotes a down-regulation in the number of MSCs. Snail1
is also required for the expression of markers specific for MSCs or
activated fibroblasts: thus, Snail1 depletion downregulates the protein
levels of S100A4, CD29, or TGF-β [6]. Because MSCs have been
demonstrated to be involved in the generation of sarcomas [7–9; see
10 as a review], in this article, we have studied the relevance of Snail1
expression in this neoplasia.
2. Materials and Methods
2.1. Mice
The generation of a murine line containing a Snail1-conditional
allele (Snail1flox), a Snail1-null allele (Snail1−), and a Cre recombi-
nase–Estrogen Receptor fusion gene under the control of β-Actin
promoter (β-Actin CreER) has been described [6]. These animals were
crossed with a p53-deficient line [11] to obtain β-Actin CreER,
Snail1−/Snail1flox, p53− mice. Animals carrying a wild-type (WT)
allele of Snail1, Snail1+/Snail1 flox, were used as controls.
All mice involved in this study were maintained in a rodent barrier
facility to guarantee the specific pathogen-free health status of the
animals. All animal experiments were previously approved by the
Animal Research Ethical Committee from the Parc de Recerca
Biomèdica de Barcelona.
2.2. Cell Culture and Generation of Stable Cell Lines
MSCs were obtained as indicated [12] and cultured in Dulbecco's
modified Eagle's medium (DMMEM) plus 10% fetal bovine serum
(FBS). As previously reported [12; see also 6], these cells were
adherent to plastic when cultured in these conditions, expressed
CD105 and CD90 (and not CD45 or CD19), and were able to
differentiate to adipocytes, osteoblasts, or chondrocytes. Snail1
depletion was obtained transfecting pMX-Cre or the empty plasmid
and selecting with 2 μg/ml puromycin for 1 week. Cell lines (3T3-
L1, C2C12, NIH-3T3.5, and 1BCR3-G) were grown in Dulbecco's
modified Eagle's medium (Invitrogen, Carlsbad, CA, USA) contain-
ing 10% FBS (Biological Industries, Kibbutz Beit Haemek, Israel),1 mM L-glutamine, and 100 U/ml penicillin-streptomycin at 37°C
in 5% CO2. Snail1 stable transfectants were obtained by transfection
of 6 μg of pcDNA3 Snail1 tagged with hemagglutinin (HA) epitope
or control pcDNA3 vector using Lipofectamine reagent (Invitrogen)
and selecting with G418 (1 mg/ml) for 3 to 4 weeks. The depletion of
Snail1 expression was generated by stable infection with retroviruses
using the pRETRO-SUPER vector and oligonucleotide 5′-
GATCCCCGATGCACATCCGAAGCCACTTCAAGA-
GAGTGGCTTCGGATGTGCATCTTTTTA-3′ or the corre-
sponding antisense oligo. The interfered murine Snail1 sequence is
shown in bold. A scrambled sequence cloned in the same vector was
used as control. Stable transfectants were obtained after selection with
1 μg/ml puromycin.
2.3. Preparation of Cell Extracts and Western Blot Analysis
Cells were washed with phosphate-buffered saline, scraped, and lysed
by the addition of 100 μl of lysis buffer [50 mM Tris-HCl (pH 6.8)
and 2% sodium dodecyl sulfate]. Thirty micrograms of proteins was
fractionated by 10%, 12%, or 15% sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and analyzed by Western blot
using antibodies corresponding to S100A4 (Thermo Scientific,
Waltham, MA, USA), CD29, CD44 (both from Abcam, Cambridge,
UK), Fibronectin (Dako, Glostrup, Denmark), p53 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA, sc-6243), Snail1 [4], Smooth
muscle actin (SMA), Pyruvate Kinase (PyrK), and Tubulin (all from
Sigma, St Louis, MO, USA).
2.4. RNA Extraction and Analysis
RNA was extracted from 1 × 106 cells with a GenElute
Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, St Louis,
MO, USA) and analyzed by quantitative reverse transcription–
polymerase chain reaction (PCR). Retrotranscription was carried out
with First Strand cDNA Synthesis Kit (Roche, Mannheim,
Germany); cDNA was amplified by quantitative PCR using SYBR
Green and a LightCycler 480 (Roche). Reactions were performed
according to the manufacturer's directions, using the following primers:
murine TGF-β1, forward—5′-CTGCAAGACCATCGACATGG-3′
and reverse—5′-GTTCCACATGTTGCTCCACA-3′; and murine
Snail1, forward—5′-GCGCCCGTCGTCCTTCTCGTC -3′ and
reverse—5′-CTTCCGCGACTGGGGGTCCT-3′. Hypoxanthine-gua-
nine phosphoribosyltransferase (forward—5′-GGCCAGACTTTGTTG-
GATTTG-3′ and reverse—5′-TGCGCTCATCTTAGGCTTTGT-
3′) and Pumilio (forward—5′-CGGTCGTCCTGAGGATAAAA-3′
and reverse—5′-CGTACGTGAGGCGTGAGTAA-3′) were used as
controls. Each reaction was performed using 100 ng of total RNA.
2.5. Tumor Xenografting
Four or five million cells were either subcutaneously or
intramuscularly (i.m.) injected into the flank of 8-week-old athymic
nude or Severe Combined Immunodeficiency mutant (SCID) mice.
Growth of the tumor was followed every other day after the first week.
Mice were killed by cervical dislocation when tumors reached a size of
1 cm3 (4 to 10 weeks after the injection, depending on the cell lines
used). At that time, the tumor area was collected, fixed in formalin,
and embedded in paraffin. Sections (4 μm) were dewaxed,
rehydrated, and stained with hematoxylin and eosin. The study was
approved by the Animal Research Ethical Committee from the Parc
de Recerca Biomèdica de Barcelona. Analysis of Snail1 expression in
tumors was carried out as indicated below for human samples.
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One hundred and nine formalin-fixed, paraffin-embedded tissue
specimens, consisting of different histologic type and grade sarcomas,
were selected from the Departments of Pathology Tumor Banks of
the Hospital del Mar (Barcelona, Spain), Hospital Virgen de la Salud
(Toledo, Spain), and Fundación Jiménez Díaz (Madrid, Spain). The
analysis of the samples was approved by the Ethical Committees of
Clinical Experimentation of the three institutions. Clinical data and
follow-up were obtained from the review of 101 patients' medical
records. Follow-up of the patients was carried out for at least 8 years
after surgery. Microscopic confirmation of diagnosis, tumor type, and
histologic grade was carried out by pathologists of the four
institutions. Specific survival was calculated from time of surgery of
the primary tumor to patient death secondary to its cancer.
Immunohistochemical analysis of Snail1 protein was performed as
previously described by using monoclonal antibody (mAb) EC3
[4,13,14], using 4-μm sections. For antigen unmasking, sections were
immersed in Tris EDTA buffer (pH 9) and boiled for 20 minutes.
Immunohistochemical staining was carried out with anti-Snail1 mAb
EC3 supernatant at 1:300 dilution using the CSA II Amplification
System (Dako), in a Dako Link platform. TGF-β expression was
determined with a rabbit polyclonal antibody against TGF-β (sc146;
Santa Cruz Biotechnology) for 1 hour at room temperature diluted at
1:100. As negative controls, the same sections incubated with
nonimmunized serum. Sections were counterstained with hematoxylin.
Immunohistochemical evaluation was conducted by two investi-
gators blinded to clinical data. Snail1 staining was graded as positive
only when nuclear staining was detectable. A tissue sample was
considered positive when at least 1% of the cells in the analyzed area
showed nuclear staining. Snail1 staining was scored semiquantita-
tively according to a scale of 0 to 300. This was the result of
multiplying the percentage of positive cells (from 1% to 100%) and
the intensity of immunoreactivity [1–3]. Samples were categorized
into the following three groups: negative expression, low expression
(lower than 10), and high expression (higher than 10). In the case of
TGF-β analysis, cells were scored as positive when cytoplasm was
observed. TGF-β expression in malignant cells was compared with
stromal cells located away from the tumor: tumors stained stronger
than stroma were considered as high expression; tumors stained
similar to stroma were considered intermediate expression, whereas
those that showed weaker staining than normal cells or did not stain at
all were considered weak/negative. Correlations between markers
were calculated by χ2 test. Survival data were analyzed according to
the Kaplan-Meier method, for the samples with high Snail1
expression versus those with null or low expression, and tested for
significance between the groups with the log-rank test. The relation of
Snail1 expression on specific survival was also analyzed by
multivariate analysis (Cox proportional risk regression model). In
all statistical tests, P values lower than .05 were considered significant.
All statistical analyses were carried out using StatView for Windows
version 5.0 (SAS Institute Inc, Cary, NC, USA).3. Results
3.1. Snail1 Increases the Tumorigenic Properties of Fibro-
blastic Cell Lines
Snail1 is required for maintenance of MSCs and other
mesenchymal cells in an undifferentiated state [6]. We examined
the relevance of this factor in the tumorigenic capability ofmesenchymal cells. We ectopically expressed Snail1 in 3T3-L1,
C2C12, and 1BR3.G cell lines (Figure 1A). As previously reported
[6], Snail1 upregulated the levels of markers of activated fibroblasts,
such as S100A4 (Figure 1A). Ectopic Snail1 expression in 3T3-L1
cells increased their tumorigenicity when injected subcutaneously into
nude mice: tumors were observed in seven of eight injections with the
Snail1-expressing cells but only after one of eight for the control cells
(Figure 1B). Histologic analyses showed that the tumors were
undifferentiated sarcomas, showing different cellular types with nuclei
of variable sizes and diameters.Mitoses were atypical. Tumors presented
high cellular density and proliferation and displayed an invasive front
infiltrating adjacent soft tissues (Figure 1C). The tumors did not show
any evidence of adipocytic differentiation. Snail1 expression was
maintained in the tumors, as assessed by immunostaining (Figure 1D).
In a similar manner, ectopic expression of Snail1 in C2C12 or 1BR3.G
cells also increased tumor formation (Figure 1B).
The inverse experiment was carried out with NIH-3T3 cells. We
used a clone of these cells, NIH-3T3.5, that expresses high levels of
endogenous Snail1 and, when injected in athymic mice, induces
tumors with features of pleomorphic sarcomas, thus, with a high
apparent mitotic index, nuclei with variable sizes and diameters,
atypical mitoses, and presence of cytoplasmic vesicles. Expression of
Snail1 was decreased in this cell line expressing a specific Snail1 short
hairpin RNA (shRNA) (Figure 1E). Snail1 down-regulation caused a
decreased expression of markers of MSCs or activated fibroblasts,
such as S100A4 or CD29 (Figure 1E). Although Snail1 down-
regulation did not alter the rate of proliferation in vitro, it did when
the cells were grafted to nude mice (Figure 1F). Analyses of tumors
postmortem indicated that the average size in control animals
(transfected with scrambled shRNA) was 1.07 cm3 (±0.18, SD) but
only 0.15 cm3 (±0.10, SD) in animals grafted with NIH-3T3.5 cells
transfected with Snail1 shRNA.
3.2. Snail1 Depletion Prevents the Generation of Sarcomas by
p53-Deficient MSCs
MSCs are not capable to originate tumors when injected into
immune-deficient mice. However, loss of p53 is sufficient to provide
tumorigenic potential to these cells [15,16], originating leiomyosar-
comalike malignancies. This model of MSC xenografting has been
used as a model of in vivo sarcomagenesis. We analyzed the relevance
of Snail1 in this system. p53-deficient MSCs were generated bearing a
floxed copy of Snail1. Surprisingly, p53 depletion increased Snail1
RNA (Figure 2A) and protein (Figure 2B). Expression of TGF-β1
gene, activated by Snail1 [6], was also increased (Figure 2A). CD29,
another stem cell marker, and other proteins upregulated in MSCs
(CD44) or in activated fibroblasts (Fibronectin and SMA) were also
increased in p53-deficient cells (Figure 2B). Snail1 expression was
eliminated by transfection of Cre; Snail1 depletion decreased the levels
of TGF-β1, CD29, CD44, S100A4, SMA, and Fibronectin in p53WT
and null (KO) cells although to different extents (Figure 2, A and B).
p53-deficient MSCs also showed a higher clonogenic capability
than control MSCs when grown in vitro in standard culture
conditions (Figure 2C). Snail1 depletion markedly decreased the
number of colonies either in WT or in p53 KO MSCs (Figure 2C).
Other properties of these cells were also differently altered by Snail1
or p53 genetic depletion. Cell migration was upregulated by p53
depletion and decreased by Snail1 deficiency in p53 KO MSCs
(Figure W1). Cell attachment to Collagen 1 was also upregulated in
these cells but was not sensitive to Snail1 depletion (Figure W1).
Figure 1. Snail1 increases the tumorigenic capability of fibroblasts in nudemice. Cells (3T3-L1, C2C12, or 1BR3.G) were stably transfected
with pcDNA3 Snail1-HA or control plasmid. (A) Expression of Snail1 and S100A4 was determined by Western blot analysis. Four millions
of cells were subcutaneously injected in the flanks of nude mice. (B) The presence of the tumors was determined after 30 (3T3-L1 and
1BR3.G) or 60 days (C2C12). The number of tumors relative to the number of injections is indicated for the different cell populations. A
histologic analysis of a tumor obtained from ·3T3-L1 Snail1 cells is presented (C); higher magnifications of the micrographs are also
shown. (D) Immunostaining with the mAb anti-Snail1 of one of these tumors is also shown. (E and F) Snail1 down-regulation inhibits the
tumorigenesis of mesenchymal cell lines. (E) Expression of Snail1 or other markers of fibroblast activation in NIH-3T3.5 fibroblasts
transfected with control or Snail1 shRNAs is shown. (F) NIH-3T3.5 transduced with a control or Snail1-specific shRNAwere injected in the
flanks of nude mice. Tumor size was measured every 4 days.
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tumors. Two months after implantation, p53 KO MSCs originate
tumors in xenografted mice when implanted subcutaneously or i.m.
An analysis of these tumors demonstrated that they presented the
features of high-grade leiomyosarcomas, with areas of extensive
muscular infiltration (Figure 3A). These tumors were mostly
composed by elongated cells with cigar-shaped nuclei (Figure 3A)
and expressed SMA (Figure W2); they also show an occasional weak
expression of muscle-specific Actin but not of MyoD1 or Desmin
(Figure W2). These tumors were detected in all the cases where p53
KO MSCs were injected i.m. and in 60% of xenografted mice when
implanted subcutaneously (Figure 3B); no tumors were observed with
WT MSCs. Depletion of Snail1 totally abrogated the capability of
p53 KO MSCs to originate tumors (Figure 3B). In accordance withthe role of Snail1 for their growth, these tumors showed abundant
Snail1 expression (Figure 3C).
3.3. Snail1 Is Expressed by Human Sarcomas
We also investigated whether Snail1 expression was detected in
human sarcomas. The analysis was carried out with mAb specific for
Snail1 and not reacting with other members of this family [4]. This
molecular tool has been previously used in several analyses [12,13,17–
19]. The analysis of a panel of sarcomas revealed that Snail1 was
expressed by 84 of 109 tumors. The reactivity was localized in the
nucleus in tumoral cells with a faint expression in the cytosol that was
not considered because Snail1 is not active in this compartment. Of
the 84 Snail1-expressing tumors analyzed, 33 expressed high levels of
Snail1, and 51 expressed low levels. Representative results are
Figure 2. Effect of Snail1 depletion on gene expression in WT or p53-deficient MSCs. (A and B) The expression of Snail1 and the indicated
markers was determined by quantitative reverse transcription–PCR (A) or Western blot analysis (B) in control or p53-deficient MSCs either
WT or KO for Snail1. (C) Cells (103) were seeded on 10-cm diameter plates in DME plus 10% FBS medium; 10 days later, they were
washed with phosphate-buffered saline, fixed with 4% p-formaldehyde, and stained with crystal violet. The figure shows a representative
experiment of two performed and the average ± range of the colony number, referred to the value obtained with WT MSCs.
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low (B and D), or Snail1 high (C, E, and F). High Snail1 expression
was particularly observed in areas of invasion (Figure 4, E and F).
Snail1 expression inversely correlated with the grade of
differentiation (P b .001). In 19 (44%) from the 43 grade 3
sarcomas, Snail1 was strongly expressed. In contrast, none of the 31
low-grade sarcoma showed high Snail1 levels. The presence of
Snail1 also varied among the different types of sarcomas (Table
W1). For instance, 10 of 15 malignant fibrohistiocytomas showed a
high expression of Snail1, whereas only 2 of 14 malignant
adipocytic sarcomas were classified in this category. Importantly,
only 1 of 17 locally aggressive tumors (i.e., fibromatosis and solitary
fibrous tumors) highly expressed Snail1.
We also determined whether Snail1 expression in sarcomas
modified the clinical outcome. A Kaplan-Meier analysis indicated
that high expression of Snail1 was associated with lower disease-free
survival (specific survival) of the patients with sarcoma with a P =
.035 (Figure 4G). Univariate and multivariate analyses were alsoperformed to verify the influence of Snail1 expression in specific
survival. As shown in Table W1, in the multivariate Cox regression
model, Snail1 expression showed an independent prognostic factor
with respect to specific survival (P = .011) as well as histologic
subtype, tumor grade, or tumor location.
A Kaplan-Meier analysis was also carried out with the 43
patients in whom the sarcomas were located in visceral, thoracic,
retroperitoneum, or intrabdominal (trunk) locations, with a worse
prognosis than the overall sarcomas. Although the number of
cases was low, high expression of Snail1 in these tumors was
also associated to a lower accumulative survival (P = .016)
(Figure 4H).
Because expression of Snail1 and TGF-β are interrelated [13], we
also determined expression of TGF-β in these samples. Tumors were
also classified as TGF-β negative/low, intermediate, or high;
representative staining are shown in Figure 5, A to C. TGF-β
expression was closely correlated with that of Snail1 (P b .001); more
than 80% of the tumors classified as Snail1 high also showed an
Figure 3. Snail1 prevents the generation of sarcomas by p53-deficient MSCs. Five million of p53-deficient MSCs, either WT or KO for
Snail1, were injected into SCID mice either in subcutaneous or i.m. locations; presence of the tumors was determined 60 days later. A
histologic analysis of a tumor obtained is presented in A; details of the micrographs are also shown in rows 2 and 4. The number of
tumors relative to the number of injections is indicated for the two implantation locations (B). (C) Immunohistochemical analysis of Snail1
expression in the tumors obtained with p53-deficient MSCs injected either subcutaneously or i.m. Bars indicate magnification.
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expression of another MSC marker, CD29, was also examined. A
significant proportion of the tumors analyzed also showed expression
of this marker (Figure 5E and Table W1) that correlated with that of
Snail1 (Figure 5F).
4. Discussion
Although Snail1 plays a well-studied function triggering EMT and
inducing the complex genetic reprogramming associated to this
transition, its role is not limited to epithelial cells. Recent evidences
indicate that Snail1 is also required for activation of fibroblasts and for
driving invasion [6,20], indicating a relevant function also in
mesenchymal cells. Although some actions of this transcriptionalfactor in both cell lineages might be common, some effects
considerably differ.
In epithelial cells, Snail1 expression promotes the acquisition of
migratory and invasive features [21], a trait also provided to
mesenchymal cells. However, its action on proliferation is different.
Although Snail1 down-regulation decreases the tumorigenic capabil-
ity of some cell lines [22,23], Snail1 transfection retards the
proliferation of most epithelial cell lines [24] and inhibits cancer-
initiating traits in prostate tumor cells [25]. Similar results are also
observed in glioblastoma multiforme: Snail1 expression in glioblas-
toma multiforme cell lines increases migration, whereas it down-
regulates tumorigenesis [26]. Probably related to this effect retarding
cell growth, Snail1 expression in epithelial neoplasias is very limited,
Figure 4. Snail1 expression is associated to a lower specific survival in human sarcomas. Expression of Snail1 was determined as
indicated in Materials and Methods section in samples from human sarcomas. Micrographs of several representative stained sections
corresponding to Snail1 (A–F) are shown. Bars indicate magnification. Kaplan-Meier analyses of specific survival with respect to Snail1
expression (high vs low or null) in 109 sarcomas or in 33 visceral, thoracic, retroperitoneum, and intrabdominal (trunk) sarcomas are
presented in G and H. The P values are indicated.
Neoplasia Vol. 16, No. 5, 2014 Snail1 and Sarcoma Generation Alba-Castellón et al. 419with the exception of few cases [18], and it is normally detected in
stromal cells close to areas of invasion or inflammation [4,27].
Snail1 action in mesenchymal cells is different because Snail1
overexpression in cell lines does not inhibit cell proliferation [6] but
provides to these cells with tumorigenic potential when grafted to
nude mice, where they induce sarcomas. We have recently described
that Snail1 prevents the differentiation of fibroblastic cell lines and
MSCs and maintains these cells in an undifferentiated state [6].
Increasing evidences indicate that MSCs carrying specific mutations
are the cause of sarcomas [7–10]; accordingly, MSCs can be
transformed depleting p53, a common alteration in human sarcomas
[28]. MSCs deficient for p53 originate high-grade sarcomas when
transplanted to nude animals [15]. It is noteworthy that p53
depletion in MSCs increases Snail1 protein and RNA. A Snail1
inhibition by p53 has been described in other systems, where p53
represses Snail1 expression through the stimulation of miR-34 [29].
According to our preliminary results, a sustained Snail1 up-regulation
by ectopic expression is not sufficient to confer tumorigenic
properties to MSCs, suggesting that additional effects dependent onp53 depletion are also necessary for MSC transformation. In any case,
it is evident that Snail1 is required for tumorigenesis, because Snail1
depletion in p53 KO MSCs totally abolishes their capability to
originate sarcomas.
Snail1 expression was observed in human sarcomas. Compared
with our studies in other neoplasms, Snail1 presents a much more
abundant expression. This might be the consequence of p53
depletion, as shown above, although it is likely that the cooperation
with other signaling pathways can enhance this up-regulation. For
instance, activation of PDGF receptor or c-Met signaling pathways
has been detected in a variety of sarcomas [30]. These pathways
activate Snail1 expression in different cellular systems [2]. We
detected differences between the various sarcomas because, in some
subtypes, such as malignant fibrohistiocytomas, the percentage of
tumors with high Snail1 expression was greater than for other
pathologies, such as liposarcomas or solitary fibrous tumors. The
elevated expression of Snail1 in the higher graded and more aggressive
sarcomas was probably responsible for the lower survival of these
patients. These results suggest a putative role for this transcriptional
Figure 5. Snail1 expression correlates with that of TGF-β and CD29 and is associated to a lower specific survival in human sarcomas.
Expression of TGF-β and CD29 was determined as indicated in Materials and Methods section in samples from human sarcomas.
Micrographs of several representative stained sections corresponding to TGF-β are shown in A to C, and a representative staining of a
CD29-positive tumor is shown in E. Bars indicate magnification. The correlation between the expression in tumors of TGF-β and Snail1 is
presented in D; that of CD29 and Snail1 is presented in F. The P values are indicated.
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more undifferentiated and associated with a more aggressive clinical
behavior. Our data also indicate that this Snail1 expression in tumors
is also associated with increased expression of TGF-β. Therefore, an
elevated Snail expression in sarcomas would be indicative of a higher
number of tumor cells with stem cell characteristics and would induce
tumors with worse prognosis. It is likely that Snail1 expression confers
higher metastatic potential to mesenchymal cells, probably through
the up-regulation of integrins required for homing or of cytokines,
such as TGF-β, that activate the metastatic niche favoring
colonization, as recently shown for colon cancer [31].
Although the involvement of Snail1 in tumorigenesis seems to be
valid for most sarcomas, it might be not for a specific type,
chondrosarcoma. It should be remarked that, unlike other conver-
sions, differentiation of MSCs to chondrocytes is not prevented by
Snail1 overexpression and is dependent on the incubation with
TGF-β3; actually, primary chondrocytes express Snail1 [6]. We have
analyzed a small number of chondrosarcomas (five), included in the
Table W1 in the category of other tumors. In these, Snail1 expression
associated with that of TGF-β and did not correlate with a lower
survival. Although the low number of cases precludes getting
conclusions, the presence of Snail1 in these sarcomas is likely to be
related with a differentiated phenotype, unlike most sarcomas. At this
respect, Snail1 has been shown to be downregulated in chondro-
sarcoma cell lines with respect to normal chondrocytes [32].
Our results on the analysis of human tumors also indicate that
determination of Snail1 expression might be very informative and
useful in clinical routine, because it is more relevant than localization
and even grade. Moreover, the identification of inhibitors of Snail1
action is being actively pursued in many laboratories with the goal ofpreventing invasion of epithelial tumors; our results suggest that these
compounds might be even more effective on sarcomas, providing new
therapies against these neoplasms.
Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.05.002.
References
[1] Thiery JP, Acloque H, Huang RY, and Nieto AM (2009). Epithelial-
mesenchymal transition in development and disease. Cell 139, 871–890.
[2] García de Herreros A and Baulida J (2012). Cooperation, amplification, and feed-
back in epithelial-mesenchymal transition. Biochim Biophys Acta 1825, 223–228.
[3] Sánchez-Tilló E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M, Darling DS,
Dean DC, Castells A, and Postigo A (2012). EMT-activating factors in cancer:
beyond EMT and tumor invasiveness. Cell Mol Life Sci 69, 3429–3456.
[4] Francí C, Takkunen M, Dave N, Alameda F, Gómez S, Rodríguez R, Escrivà M,
Montserrat-Sentís B, Baró T, and Garrido M, et al (2006). Expression of Snail
protein in tumor-stroma interface. Oncogene 25, 5134–5144.
[5] DeCraene B and Berx G (2013). Regulatory networks defining EMT during
cancer initiation and progression. Nat Rev Cancer 13, 97–110.
[6] Batlle R, Alba-Castellón L, Loubat-Casanovas J, Armenteros E, Francí C,
Stanisavljevic J, Banderas R, Martin-Caballero J, Bonilla F, and Baulida J, et al
(2013). Snail1 controls TGF-β responsiveness and differentiation of mesenchymal
stem cells. Oncogene 32, 3381–3389.
[7] Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C,
Clements MO, Bourboulia D, Pedley RB, and Moncada S, et al (2007).
Transformation of human mesenchymal stem cells increases their dependency on
oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 104,
6223–6228.
[8] Rodríguez R, Rubio R, Masip M, Catalina P, Nieto A, de la Cueva T, Arriero M,
San Martin N, de la Cueva E, and Balomenos D, et al (2009). Loss of p53 induces
tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia 11, 397–407.
Neoplasia Vol. 16, No. 5, 2014 Snail1 and Sarcoma Generation Alba-Castellón et al. 421[9] Rodríguez R, Tornin J, Suarez C, Astudillo A, Rubio R, Yauk C, Williams A,
Rosu-Myles M, Funes JM, and Boshoff C, et al (2013). Expression of FUS-
CHOP fusion protein in immortalized/transformed human mesenchymal stem
cell drives moxoid liposarcoma formation. Stem Cells 31, 2061–2072.
[10] Rodriguez R, Rubio R, andMenendez P (2012). Modelling sarcomagenesis using
multipotent mesenchymal stem cells. Cell Res 22, 62–77.
[11] Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel
JS, and Bradley A (1992). Mice deficient for p53 are developmentally normal
buts susceptible to spontaneous tumours. Nature 356, 215–221.
[12] Soleimani M and Nadri S (2009). A protocol for isolation and culture of
mesenchymal stem cells from mouse bone marrow. Nat Protoc 4, 102–106.
[13] Francí C, Gallén M, Alameda F, Baró T, Iglesias M, Virtanen I, and García de
Herreros A (2009). Snail1 protein in the stroma as a new putative prognosis
marker for colon tumours. PLoS One 4, e5595.
[14] Vincent T, Neve EP, Johnson JR, Kukalev A, Rojo F, Albanell J, Pietras K,
Virtanen I, Philipson L, and Leopold PL, et al (2009). A SNAIL1–SMAD3/4
transcriptional repressor complex promotes TGF-β-mediated epithelial–mesen-
chymal transition. Nat Cell Biol 11, 943–950.
[15] Rubio R, García-Castro J, Gutiérrez-Aranda I, Paramio J, Santos M, Catalina P,
Leone PE, Menendez P, and Rodríguez R (2010). Deficiency in p53 but not
retinoblastoma induces the transformation of mesencnymal stem cells in vitro
and initiates leiomyosarcoma in vivo. Cancer Res 70, 4185–4194.
[16] Rubio R, Gutierrrez-Aranda I, Sáez-Castillo AI, Labarga A, Rosu-Myles M,
Gonzalez-Garcia S, Toribio ML, Menendez P, and Rodriguez R (2013). The
differentiation satge of p53-Rb-deficient bone marrow mesenhcymal stem cells
imposes the phenotype of in vivo sarcoma development.Oncogene 32, 4970–4980.
[17] Peinado H, Moreno-Bueno G, Hardisson D, Pérez-Gómez E, Santos V,
Mendiola M, de Diego JI, Nistal M, Quintanilla M, and Portillo F, et al (2008).
Lysyl oxidase–like 2 as a new por prognosis marker of squamous cell carcinomas.
Cancer Res 68, 4541–4550.
[18] Geradts J, de Herreros AG, Su Z, Burchette J, Broadwater G, and Bachelder RE
(2011). Nuclear Snail-1 and nuclear ZEB1 protein expression in invasive and
intraductal human breast carcinomas. Hum Pathol 42, 1125–1131.
[19] Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG, Matias-
Guiu X, and Prat J (2012). Epithelial to mesenchymal transition in early stage
endometrioid endometrial carcinoma. Hum Pathol 43, 632–643.
[20] Rowe RG, Li XY, Hu Y, Saunders TL, Virtanen I, Garcia de Herreros A, Becker
KF, Ingvarsen S, Engelholm LH, and Bommer GT, et al (2009). Mesenchymal
cells reactivate Snail1 expression to drive three-dimensional invasion programs.
J Cell Biol 184, 399–408.[21] Garcia de Herreros A, Peiró S, Nassour M, and Savagner P (2010). Snail family
regulation and epithelial mesenchymal transitions in breast cancer progression.
J Mammary Gland Biol Neoplasia 15, 135–147.
[22] Olmeda D, Moreno-Bueno G, Flores JM, Fabra A, Portillo F, and Cano A (2007).
SNAI1 is required for tumor growth and lymph node metastasis of human breast
carcinoma MDA-MB-231 cells. Cancer Res 67, 11721–11731.
[23] Olmeda D, Montes A, Moreno-Bueno G, Flores JM, Portillo F, and Cano A
(2008). Snai1 and Snai2 collaborate on tumor growth and metastasis properties
of mouse skin carcinoma cell lines. Oncogene 27, 4690–4701.
[24] Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, and Nieto MA (2004).
Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18,
1131–1143.
[25] Celià-Terrassa T, Meca-Cortés O, Mateo F, de Paz AM, Rubio N, Arnal-Estapé
A, Ell BJ, Bermudo R, Díaz A, and Guerra-Rebollo M, et al (2012). Epithelial-
mesenchymal transition can suppress major attributes of human epithelial tumor-
initiating cells. J Clin Invest 122, 1849–1868.
[26] Savary K, Caglayan D, Caja L, Tzavlaki K, Bin Nayeem S, Bergström T, Jiang Y,
Uhrbom L, Forsberg-Nilsson K, and Westermark B, et al (2013). Snail depletes
the tumorigenic potential of glioblastoma. Oncogene 32, 5409–5420.
[27] Rosivatz E, Becker KF, Kremmer E, Schott C, Blechschmidt K, Höfler H, and
Sarbia M (2006). Expression and nuclear localization of Snail, an E-cadherin
repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch
448, 277–287.
[28] Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM,
Marechal V, Chen J, BrennanMF, and Levine AJ (1994). Molecular abnormalities
of mdm2 and p53 genes in adult soft tissues sarcomas. Cancer Res 54, 794–799.
[29] Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D,
and Fearon ER, et al (2011). A p53/miRNA-34 axis regulates Snail1-dependent
cancer cell epithelial–mesenchymal transition. J Cell Biol 195, 417–433.
[30] Helman LJ andMeltzer P (2003). Mechanisms of sarcoma development.Nat Rev
Cancer 3, 685–694.
[31] Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Céspedes MV,
Sevillano M, Nadal C, Jung P, and Zhang XH, et al (2012). Dependency of
colorectal cancer on a TGF-β-driven program in stromal cells for metastasis
initiation. Cancer Cell 22, 571–584.
[32] Fitzgerald MP, Gourronc F, Teoh ML, Provenzano MJ, Case AJ, Martin JA,
and Domann FE (2011). Human chondrosarcomas cells acquire an epithelial-
like gene expression pattern via an epigenetic switch: evidence for
mesenchymal-epithelial transition during sarcomagenesis. Sarcoma 2011
[ID598218].
